INHBB Specific Neutra™ Antibody Products

Inhibin Beta B Subunit (INHBB) is a secreted component joining with the alpha subunit to form a dimeric complex of activins or inhibins. Activins activate the secretion of follitropin, while inhibins play an opposite role. INHBB plays important modulating roles in tumor development and progression.

Its Gene ID: 3625, UniProtKB ID: P09529, and OMIM ID: 147390.

Functions of INHBB in Tumor Development

INHBB has a high therapeutic potential to promote tumor elimination in various cancers. INHBB knockdown could activate the TGF-β pathway and elicit a series of pro-tumor responses shown in Figure 1.

• Promotes tumor proliferation through the phosphorylation of Smad2/3 and DNA synthesis.
• Promotes tumor migration and invasion through up-regulating MMP and VEGF.
• Promotes tumor drug resistance through the enhancement of epithelial-mesenchymal transition.

Fig.1 Diminished INHBB promotes tumor progression through the TGF-β pathway.¹

Roles of Activins / Inhibins in Reproductive and Cancer Physiology

Activin B (βB / βB dimers) and inhibin B (α / βB dimers) are encoded by INHBB and INHAB / INHBB, respectively. The matured activin B and inhibin B play extensive physiological and pathological roles.

• In normal physiological conditions (Fig.2A), the interaction between inhibins and beta glycan or TGFBR3L could limit the bioactivity of activins and maintain cellular homeostasis by modulating the phosphorylation of Smad2/3.
• In pathological conditions (Fig.2B), the inactivation of the interaction between inhibins and their co-receptors leads to the activin activity loss of control, which results in reproductive and cancer pathology.

Fig.2 Inhibin/activin roles in reproductive and cancer biology.²

Creative Biolabs offers anti-INHBB antibodies with high affinity and specificity for immunoassays to detect the existence and measure the level of INHBB. Due to strict quality controls during antibody production, our customers can use these anti-INHBB antibodies without hesitation.

REFERENCES

1. Zou, Guoying, et al. "Inhibin B suppresses anoikis resistance and migration through the transforming growth factor‐β signaling pathway in nasopharyngeal carcinoma." Cancer Science 109.11 (2018): 3416-3427.
2. Hagg, Adam, et al. "Targeting activins and inhibins to treat reproductive disorders and cancer cachexia." Journal of Endocrinology 258.1 (2023).